C
ACADIA Pharmaceuticals Inc.
ACAD
$16.62
$0.301.84%
C
Hold
1/7/2025Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to C- from D+ on 1/7/2025 due to a significant increase in the valuation index, efficiency index and volatility index. Total capital increased 9.09% from $574.36M to $626.55M.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to C- from D+ on 1/7/2025 due to a significant increase in the valuation index, efficiency index and volatility index. Total capital increased 9.09% from $574.36M to $626.55M.
D
Sell
8/8/2024Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D+ from E+ on 8/8/2024 due to a substantial increase in the efficiency index and valuation index. Net income increased 101.69% from $16.56M to $33.39M, and total capital increased 9.68% from $523.69M to $574.36M.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D+ from E+ on 8/8/2024 due to a substantial increase in the efficiency index and valuation index. Net income increased 101.69% from $16.56M to $33.39M, and total capital increased 9.68% from $523.69M to $574.36M.
E
Sell
4/25/2024Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 4/25/2024 due to a decline in the total return index and volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 4/25/2024 due to a decline in the total return index and volatility index.
D
Sell
1/4/2024Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index.
E
Sell
10/18/2023Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 10/18/2023 due to a decline in the volatility index and valuation index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 10/18/2023 due to a decline in the volatility index and valuation index.
D
Sell
6/20/2023Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 6/20/2023 due to an increase in the total return index and volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 6/20/2023 due to an increase in the total return index and volatility index.
E
Sell
6/2/2023Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 6/2/2023 due to a decline in the valuation index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 6/2/2023 due to a decline in the valuation index.
D
Sell
5/15/2023Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 5/15/2023 due to a substantial increase in the growth index and volatility index. Operating cash flow increased 24.82% from -$23.85M to -$17.93M.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 5/15/2023 due to a substantial increase in the growth index and volatility index. Operating cash flow increased 24.82% from -$23.85M to -$17.93M.
E
Sell
5/11/2023Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 5/11/2023 due to a decline in the volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 5/11/2023 due to a decline in the volatility index.
D
Sell
3/14/2023Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 3,181.16% from -$727 to -$23.85M, earnings per share declined from -$0.1679 to -$0.2576, and EBIT declined 49.24% from -$30.87M to -$46.06M.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 3,181.16% from -$727 to -$23.85M, earnings per share declined from -$0.1679 to -$0.2576, and EBIT declined 49.24% from -$30.87M to -$46.06M.
D
Sell
2/9/2023Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D on 2/8/2023 due to a major decline in the growth index and solvency index. Total revenue declined 2.86% from $134.56M to $130.71M, and the quick ratio declined from 4.29 to 4.23.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D on 2/8/2023 due to a major decline in the growth index and solvency index. Total revenue declined 2.86% from $134.56M to $130.71M, and the quick ratio declined from 4.29 to 4.23.
D
Sell
8/12/2022Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 8/12/2022 due to a significant increase in the growth index. Operating cash flow increased 82.8% from -$76.33M to -$13.13M, EBIT increased 70.22% from -$113.02M to -$33.65M, and earnings per share increased from -$0.7012 to -$0.2104.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 8/12/2022 due to a significant increase in the growth index. Operating cash flow increased 82.8% from -$76.33M to -$13.13M, EBIT increased 70.22% from -$113.02M to -$33.65M, and earnings per share increased from -$0.7012 to -$0.2104.
D
Sell
6/13/2022Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 6/13/2022 due to a decline in the total return index and volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 6/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 05/16/2022.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index, solvency index and total return index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index, solvency index and total return index.
D
Sell
5/2/2022Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 5/2/2022 due to an increase in the volatility index and valuation index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 5/2/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/1/2022Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 5/1/2022 due to a decline in the total return index and volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/20/2022Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index and valuation index. Earnings per share declined from -$0.09 to -$0.2679, EBIT declined 191.86% from -$15.3M to -$44.66M, and operating cash flow declined 35.49% from -$17.06M to -$23.12M.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index and valuation index. Earnings per share declined from -$0.09 to -$0.2679, EBIT declined 191.86% from -$15.3M to -$44.66M, and operating cash flow declined 35.49% from -$17.06M to -$23.12M.
D
Sell
11/9/2021Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D on 11/8/2021 due to a substantial decline in the total return index, volatility index and solvency index.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D on 11/8/2021 due to a substantial decline in the total return index, volatility index and solvency index.
D
Sell
2/28/2020Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 2/28/2020 due to a substantial increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.01 to 0.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 2/28/2020 due to a substantial increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.01 to 0.
D
Sell
10/16/2018Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 10/16/2018 due to an increase in the total return index and volatility index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D- from E+ on 10/16/2018 due to an increase in the total return index and volatility index.
E
Sell
10/1/2018Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 10/1/2018 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.97 to 5.76.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to E+ from D- on 10/1/2018 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.97 to 5.76.
D
Sell
3/3/2017Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 3/3/2017 due to a decline in the solvency index, efficiency index and valuation index. The quick ratio declined from 15.17 to 12.59, total capital declined 10.32% from $578.06M to $518.41M, and net income declined 9.89% from -$71.61M to -$78.7M.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 3/3/2017 due to a decline in the solvency index, efficiency index and valuation index. The quick ratio declined from 15.17 to 12.59, total capital declined 10.32% from $578.06M to $518.41M, and net income declined 9.89% from -$71.61M to -$78.7M.
D
Sell
11/8/2016Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 11/8/2016 due to an increase in the growth index, solvency index and valuation index. Total revenue increased 5,330.93% from $97 to $5.27M, operating cash flow increased 13.19% from -$56.75M to -$49.26M, and the quick ratio increased from 14.27 to 15.17.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 11/8/2016 due to an increase in the growth index, solvency index and valuation index. Total revenue increased 5,330.93% from $97 to $5.27M, operating cash flow increased 13.19% from -$56.75M to -$49.26M, and the quick ratio increased from 14.27 to 15.17.
D
Sell
8/5/2016Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 8/5/2016 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 43.33% from -$49.76M to -$71.32M, the quick ratio declined from 21.68 to 14.27, and total capital declined 8.18% from $445.25M to $408.82M.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 8/5/2016 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 43.33% from -$49.76M to -$71.32M, the quick ratio declined from 21.68 to 14.27, and total capital declined 8.18% from $445.25M to $408.82M.
D
Sell
5/6/2016Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 5/6/2016 due to an increase in the solvency index, efficiency index and total return index. Total capital increased 122.89% from $199.76M to $445.25M, and the quick ratio increased from 9.9 to 21.68.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D from D- on 5/6/2016 due to an increase in the solvency index, efficiency index and total return index. Total capital increased 122.89% from $199.76M to $445.25M, and the quick ratio increased from 9.9 to 21.68.
D
Sell
3/11/2016Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 13.58 to 9.9.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 13.58 to 9.9.
D
Sell
8/7/2015Downgrade
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D from D+ on 8/7/2015 due to a major decline in the volatility index, efficiency index and solvency index. The quick ratio declined from 17.94 to 14.05, total capital declined 10.27% from $285.09M to $255.82M, and net income declined 2.47% from -$40.38M to -$39.38M.
ACADIA Pharmaceuticals Inc. (ACAD) was downgraded to D from D+ on 8/7/2015 due to a major decline in the volatility index, efficiency index and solvency index. The quick ratio declined from 17.94 to 14.05, total capital declined 10.27% from $285.09M to $255.82M, and net income declined 2.47% from -$40.38M to -$39.38M.
D
Sell
2/27/2015Upgraded
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D+ from D on 2/27/2015 due to a major increase in the volatility index, solvency index and total return index.
ACADIA Pharmaceuticals Inc. (ACAD) was upgraded to D+ from D on 2/27/2015 due to a major increase in the volatility index, solvency index and total return index.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
